Logo image of SPRO

SPERO THERAPEUTICS INC (SPRO) Stock Fundamental Analysis

NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD

2.5  +0.37 (+17.37%)

After market: 2.49 -0.01 (-0.4%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SPRO. SPRO was compared to 560 industry peers in the Biotechnology industry. The financial health of SPRO is average, but there are quite some concerns on its profitability. SPRO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SPRO had negative earnings in the past year.
In the past year SPRO has reported a negative cash flow from operations.
SPRO had negative earnings in 4 of the past 5 years.
In the past 5 years SPRO always reported negative operating cash flow.
SPRO Yearly Net Income VS EBIT VS OCF VS FCFSPRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

SPRO's Return On Assets of -89.77% is on the low side compared to the rest of the industry. SPRO is outperformed by 72.32% of its industry peers.
With a Return On Equity value of -206.31%, SPRO is not doing good in the industry: 68.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -89.77%
ROE -206.31%
ROIC N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
SPRO Yearly ROA, ROE, ROICSPRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

SPRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRO Yearly Profit, Operating, Gross MarginsSPRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRO has been increased compared to 1 year ago.
Compared to 5 years ago, SPRO has more shares outstanding
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRO Yearly Shares OutstandingSPRO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SPRO Yearly Total Debt VS Total AssetsSPRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SPRO has an Altman-Z score of -8.73. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SPRO (-8.73) is worse than 70.71% of its industry peers.
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.73
ROIC/WACCN/A
WACC9.49%
SPRO Yearly LT Debt VS Equity VS FCFSPRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.56 indicates that SPRO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.56, SPRO is doing worse than 69.46% of the companies in the same industry.
SPRO has a Quick Ratio of 2.56. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
SPRO has a Quick ratio of 2.56. This is in the lower half of the industry: SPRO underperforms 67.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.56
Quick Ratio 2.56
SPRO Yearly Current Assets VS Current LiabilitesSPRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SPRO have decreased strongly by -341.51% in the last year.
SPRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.83%.
The Revenue has been growing by 21.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-341.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.17%
Revenue 1Y (TTM)-59.83%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-36.61%

3.2 Future

Based on estimates for the next years, SPRO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.25% on average per year.
SPRO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.51% yearly.
EPS Next Y0.01%
EPS Next 2Y37.68%
EPS Next 3Y-12.65%
EPS Next 5Y20.25%
Revenue Next Year-100%
Revenue Next 2Y-81.73%
Revenue Next 3Y-5.87%
Revenue Next 5Y19.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SPRO Yearly Revenue VS EstimatesSPRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M 200M
SPRO Yearly EPS VS EstimatesSPRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRO Price Earnings VS Forward Price EarningsSPRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRO Per share dataSPRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

SPRO's earnings are expected to decrease with -12.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.68%
EPS Next 3Y-12.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPERO THERAPEUTICS INC

NASDAQ:SPRO (5/30/2025, 6:55:17 PM)

After market: 2.49 -0.01 (-0.4%)

2.5

+0.37 (+17.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners25.51%
Inst Owner Change20.62%
Ins Owners5.2%
Ins Owner Change17.07%
Market Cap139.78M
Analysts77.78
Price Target5.1 (104%)
Short Float %1.55%
Short Ratio4.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.63%
Min EPS beat(2)-20.18%
Max EPS beat(2)55.44%
EPS beat(4)3
Avg EPS beat(4)15.94%
Min EPS beat(4)-20.18%
Max EPS beat(4)55.44%
EPS beat(8)6
Avg EPS beat(8)115.87%
EPS beat(12)9
Avg EPS beat(12)174.93%
EPS beat(16)10
Avg EPS beat(16)130.1%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)-52%
EPS NY rev (1m)0%
EPS NY rev (3m)-119.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.14
P/FCF N/A
P/OCF N/A
P/B 4.13
P/tB 4.13
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.8
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.77%
ROE -206.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.56
Quick Ratio 2.56
Altman-Z -8.73
F-Score2
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-341.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.17%
EPS Next Y0.01%
EPS Next 2Y37.68%
EPS Next 3Y-12.65%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-59.83%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-36.61%
Revenue Next Year-100%
Revenue Next 2Y-81.73%
Revenue Next 3Y-5.87%
Revenue Next 5Y19.51%
EBIT growth 1Y-370.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-536.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-536.96%
OCF growth 3YN/A
OCF growth 5YN/A